The Ames assay was used to investigate the mutagenicity of several phthalate esters as an approximation of their carcinogenic potential. The ortho diesters, dimethyl phthalate (DMP) and diethyl phthalate (DEP) produced a positive dose-related mutagenic response with Salmonella TA100, but only in the absence of S-9 liver enzymes. Dibutyl, di(2-ethylhexyl), mono(2-ethylhexyl), and butyl benzyl phthalate as well as the dimethyl isophthalate and terephthalates and the trimethyl ester, trimellitate, were not mutagenic with TA100 or TA98 in the presence or absence of S-9. In a host-mediated assay, extracts of 24-hr urines of rats injected IP with DMP (2 g/kg) were not mutagenic to TA100 at levels up to 8 equivalent-ml of urine/plate (representing 30% of their daily urinary output). In vitro studies revealed that S-9 associated esterase hydrolyzed DMP to the monoester and methanol and eliminated its mutagenicity. Whole rat skin was shown to have about 1.5% of the DMP-esterase activity of liver, when compared on a wet weight basis. An in vitro binding study indicated that epidermal macromolecules bound DMP at a severalfold greater rate than hepatic macromolecules. Thus, both the mutagenicity and binding of DMP are inversely related to the metabolism of this compound. These results suggest that skin could be at high risk for a mutagenic/carcinogenic insult.
Introduction
Since there are scant data on the mutagenic and carcinogenic potential of a variety of phthalate esters, the Ames assay was used to investigate the mutagenicity of some of these compounds as an approximation of their carcinogenic potential. This paper presents evidence for the mutagenesis of dimethyl phthalate (DMP) and diethyl phthalate (DEP), along with additional studies on the metabolism of DMP and its binding to macromolecules.
DMP is a widely used insect repellent which is available to the general public as an active ingredient in commercial products. In its pure form it is used by agricultural workers in doses up to 100 mg/kg applied directly to the skin (1) ing the many people exposed to DMP as well as the potentially large doses to which they may be exposed, further research on the mutagenic effects of this chemical is well justified.
A literature search in the area of mutagenicity of DMP revealed relatively few studies. One study by Pilinskaya et. al. (2) reported no increase in chromosomal aberrations in bone marrow cells of white mice administered DMP intraperitoneally (dose not cited). Another study by Tsuchiya and Hattori (3) also reported no increase in chromosomal damage in human leukocytes treated in culture with 20 ,ug/ml of DMP. On the other hand, Yurchenko (4) did report a significant increase in chromosomal aberrations in hepatocytes from rats treated topically with 1250 mg/kg DMP five times per week for one month. Rats administered only a single topical dose displayed no significant increase in chromosomal aberrations. Thus, DMP's topical use as an insect repellent and the observation of hepatic chromosomal damage would suggest skin and liver, respectively, as potential sites for mutagenic/carcinogenic effects. 104 
Methods

Mutagenesis
The standard Ames bacterial mutagenicity assay (5) was used with several modifications as described by Batzinger et al. (6) . The major modifications included shifting the histidine and biotin (at concentrations of 50 and 15 g/plate, respectively) from the top to the bottom agar, and reducing the glucose to 67.5 mg/plate in the bottom agar. Each phthalate ester was tested with Salmonella typhimurium strains TA98 and TA100 in the presence and absence of S-9 liver microsomal fraction from male SpragueDawley rats induced with Aroclor 1254.
Host-Mediated Assay
Male Sprague-Dawley rats (approximately 350 g) were injected IP with 2 g/kg of DMP and 24-hr urine was collected. The urine from 12 animals was pooled. Five such pools were collected. The urine (not further acidified) was extracted once with n-butanol which was then evaporated. The Preparation, Incubation and Treatment of Liver S-9 A 0.15 ml aliquot of DMP (4000 ,ug/ml water) was added to 2 ml of E medium plus 0.5 ml of S-9 mix (5). The mixture was shaken at 37°C for various time periods up to 1 hr. The reaction was terminated by the addition of 0.4 ml of 1.0 N HCI. After centrifugation at 1000 g for 10 min, 2 ml of the acidified supernatant (pH 1.5) was extracted twice with chloroform.
Chemical Analysis of In Vitro Skin and Liver Extracts
The rate of in vitro metabolism of DMP to MMP and methanol was measured by the formation of MMP. The chloroform extracts from the liver S-9 and the skin incubations were analyzed for MMP by the TLC-spectrophotometric method described in the above section on chemical analysis of urine. The rate of metabolism was determined over the linear range of metabolism for each tissue.
In addition, the in vitro metabolism of DMP to methanol by skin slices was investigated using the basic method of Wood and Siddiqui (7) . A slight modification of the method allowed for simultaneous determination of formaldehyde formation. This was accomplished by measuring the amount of formaldehyde formed in the presence and absence of KMnO4, which is used to convert methanol to formaldehyde. In the presence of KMnO4, the total of methanol plus formaldehyde is measured. In the absence of KMnO4, only the presence of formaldehyde is detected. The difference between the two procedures yields the amount of methanol formed.
Preparation of Epidermal and Hepatic Homogenates
The homogenized epidermis was prepared by modifications of previously described techniques (8) . After the removal of the entire dorsal skin as described above, it was immersed in distilled water at 50°C for 30 sec and then immediately transferred to iced water for another half minute. The epidermal layer was then scraped off with a scalpel, suspended in 2-3 ml of ice cold PBS (pH 7.4) and homogenized. The homogenate was then strained through a fine nylon mesh.
A rat was decapitated and following exsanguination the in situ liver was perfused with 30-40 ml of PBS (pH 7.4) via the hepatoportal vein. The liver was then removed and homogenized in PBS at a ratio of 1 to 3 (w/v). The homogenate was strained through fine nylon mesh.
A 1-ml aliquot of each of epidermal and liver homogenates was mixed with 1 ml of 14C-carbonyl- 
Determination of Macromolecular Binding
To determine macromolecular binding, the method of Jollow et al. (9) was employed. Successive washings with TCA, 80% ethanol and acetone were continued until the 1 ml aliquots of the wash solution (dissolved in ACS Aquasol scintillation fluid) produced counts equivalent to background on a Packard Tricarb liquid scintillation spectrometer.
The final acetone washed TCA precipitate was taken to dryness and weighed to determine the mg of dry weight. Finally, the macromolecular residue was solubilized in NCS tissue solubilizer (Amersham) for counting.
Results
The results from the modified Ames mutagenic assay of phthalic acid (PA), DMP and DEP in TA100 in the absence of S-9 are shown in Table 1 resented essentially a doubling of the basal level of reversion. These three compounds were not mutagenic when tested with the TA98 strain of Salmonella (data not shown).
The effect of S-9 liver extract on DMP-and DEPinduced mutations is presented in Table 2 . Lucanthone (Luc) was used as the positive control to demonstrate the effectiveness of the S-9 fraction in activating a nondirect-acting mutagen. In the absence of S-9, DMP and DEP produced a positive mutagenic response, confirming the data presented in Table 1 . With S-9 and NAD or NADP added to the system, the positive response was reversed. It is important to note that S-9 alone (without the cofactors) also eliminated the mutagenic resDonse.
A number of other phthalate esters were tested in our modified Ames assay. Each phthalate was assayed with bacterial strains TA100 and TA98, both in the presence and absence of S-9 liver extract. All of these phthalate esters failed to produce a positive response at concentrations up to 1000 ,ug/plate. The compounds tested were: di-n-butyl phthalate, di(2-ethylhexyl) phthalate, mono(2-ethylhexyl) phthalate and butyl benzyl phthalate (data not shown). Figure 1 shows the mutagenic dose response for DMP extended over a broader range of concentrations, i.e., from 1 to 4 mg/plate. A positive doserelated mutagenic response was associated with a dose-related decrease in survival of the cells of the TA100 tester strain. If the absolute number of revertants per plate were corrected for percent survival, an even greater mutagenic response would have been seen than the 3-to 3.5-fold response at 4 mg/plate.
The structure-activity relationship (SAR) ofDMP was investigated by testing three other methyl phthalates in the Ames assay with TA100 and TA98, either in the absence or presence of S-9 activation. Dimethyl terephthalate (I), dimethyl isophthalate (II) and trimethyl trimellitate (III) were all negative in the mutagenesis assay.
The results of a host-mediated mutagenic assay of DMP in rats are presented in Figure 2 . There were no statistically significant differences in the number of revertants per plate for control or treated Since the urinary extracts used in the hostmediated assay were obtained by a single n-butanol extraction of urine that was not further acidified beyond its native pH (see methods), further experiments were conducted to determine the phthalic acid-containing components in urine of treated rats using more exhaustive extractions from samples that were acidified to pH 1-2 with HCl. The data 107 are shown in Table 3 . DMP and MMP were found at levels of 0.14 and 15.70 mg/ml, representing 0.6 and 67.0% ofthe injected dose, respectively. Once again, no other phthalic acid-containing derivatives were detected. Thus, DMP represented less than 1% of all phthalic acid-containing molecules excreted in 24 hr.
Although these results suggest systemic inactivation of the mutagenic activity of DMP, it should be recalled that the major route of human exposure is topical. Therefore, the ability of rat skin to metabolize DMP to MMP and thus inactivate the diester was investigated. The results from three separate experiments performed to study the in vitro metabolism of DMP by rat skin are presented in Table 4 . In the first experiment, only MMP formation was assayed; it was found to be 3.47 nmole/hr/mg tissue. Since the de-esterification of DMP should also result in the formation of methanol, the rate for this product was measured in a second experiment. It was found to be 2.58 nmole/ hr/mg tissue. In a third experiment the stoichio- nmole MMP formed/hr/mg liver (wet). metric relationship between MMP and methanol was examined and found to be 1:1. The rate of formaldehyde formation was also investigated in this latter experiment, but none of this product could be detected. It should be noted that the rate of de-esterification of DMP by whole skin is approximately 1.5% of the rate seen in the liver, when compared on a mg wet weight basis.
Given the markedly lower rate of metabolism of DMP to a nonmutagenic metabolite in skin relative to liver, the in vitro binding of DMP to tissue macromolecules in these two tissues was investigated. The results are shown in Table 5 . 14C-Carbo nyl-labeled DMP was found to bind to hepatic and epidermal macromolecules at levels of 0.17 and 0.98 nmole/mg tissue (dry weight-TCA precipitable), respectively.
Discussion and Conclusion
The positive dose-related mutagenic response of TA100 to DMP and DEP ( The elimination ofthe positive mutagenic response by S-9 liver microsomes (Table 2) implicates metabolism as a second important modifying factor. Lack of involvement of the cofactors NAD and NADP indicates that the classical mixed-function oxidase (MFO) system is not involved in the apparent metabolic elimination of the mutagenic response. Liver S-9 (Table 4) readily metabolizes DMP to MMP, which has been shown to be a nonmutagenic compound in the Ames assay. These results suggest that a S-9 associated esterase activity is responsible for the elimination of the mutagenic effect. Results from the host-mediated mutagenic assay (Fig. 2 ) support this idea. In this assay approximately 97% of the phthalate ester content of the urine extract is MMP. Thus, the lack of a positive mutagenic response along with the preponderance of monoester indicate the importance of DMP-monoesterase activity in eliminating the mutagenic effect and possibly in affording protection to tissue exposed to DMP.
It should be noted that 8 equivalent ml of treated urine are negative in the mutagenic assay in spite of containing approximately 480 jig of DMP, an amount which results in a statistically significant increase, albeit small, in the mutation rate in the direct assay. It In spite of the substantial hepatic metabolism of DMP by rats, the only positive mammalian mutagenic response to this compound was observed by Yurchenko (4) in rat liver. In light of the inverse correlation of binding as well as of mutagenicity to metabolism of DMP, one would have expected the liver to be relatively refractory to a mutagenic event. Thus, based on Yurchenko's observation, either the hepatic metabolism of rats is insufficient to protect the liver from chronic administration of DMP or neither the Ames assay nor the TLC analytical methodology used in these studies is adequate to detect a mutagenic metabolite formed from the products of the mono-esterase activity. If the former explanation prevails, then skin with its considerably lower level of mono-esterase activity might well be at even greater risk than liver to incur a mutagenic/carcinogenic event. On the other hand, if the latter possibility is correct, then the greater rate of hepatic monoesterase activity would suggest liver, rather than skin, as the primary target site.
In conclusion, based on the results presented, we would recommend an in vitro bioassay for the carcinogenesis of DMP, particularly in view of the wide spread exposure of the human population to this compound. These results would argue for a bioassay protocol that would include the topical application of DMP.
